No clinical data could be extracted as the provided text contains only web shop instructions.
Do NT-proBNP and hs-cTnT predict the incidence and prognosis of anthracycline-caused cardiovascular toxicities in Non-Hodgkin's Lymphoma patients?
Non-Hodgkin's Lymphoma (NHL) patients treated with anthracyclines
Measurement of NT-proBNP and hs-cTnT biomarkers
Incidence of symptomatic cardiovascular toxicities (CVTs) and prognosishard clinical
Elevated NT-proBNP and hs-cTnT levels can predict symptomatic cardiovascular toxicities and poor prognosis in NHL patients receiving anthracyclines.
An NT-proBNP-ER ≥ 2.56 or hs-cTnT ≥ 11.68 ng/L, individually or combined, are significant predictors of symptomatic CVTs. Exceeding these thresholds indicates a poor prognosis in NHL patients treated with anthracyclines.
Building similarity graph...
Analyzing shared references across papers
Loading...
Guangjian Su
Fujian Medical University
Wei Peng
Ministry of Agriculture and Rural Affairs
Yan Chen
Southwest Petroleum University
Clinical Laboratory
Building similarity graph...
Analyzing shared references across papers
Loading...
Su et al. (Thu,) conducted a other in Non-Hodgkin's Lymphoma. NT-proBNP and hscTnT was evaluated. No clinical data could be extracted as the provided text contains only web shop instructions.
synapsesocial.com/papers/69d893c96c1944d70ce04c29 — DOI: https://doi.org/10.7754/clin.lab.2025.240339
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: